Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?
Solid Biosciences Inc (SLDB) has seen significant stock growth, gaining approximately 75% in the last six months and over 190% in the past year. The company is advancing its gene therapy programs, including a Phase 3 trial for its drug candidate SGT-003 aimed at treating Duchenne muscular dystrophy. Analysts predict that SLDB's stock could potentially double in the next 12 months as the company continues its development efforts.
- ▪Solid Biosciences Inc has gained roughly 75% over the past six months.
- ▪The stock surged more than 190% over the past 12 months.
- ▪The company has begun a Phase 3 trial of its drug candidate SGT-003.
Opening excerpt (first ~120 words) tap to expand
Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months? Abdul Rahman Wed, May 20, 2026 at 5:36 AM PDT 2 min read SLDB -6.61% Trade SLDB on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational. Learn more Solid Biosciences Inc (NASDAQ:SLDB) is one of the best gene therapy stocks to buy in 2026. The stock has been a big win for investors, having gained roughly 75% over the past six months and surged more than 190% over the past 12 months.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Yahoo Finance.